The effect of paroxetine on heart rate variability in patients with major depressive disorder: A systematic review and meta-analysis.

Autor: de Oliveira CM; Autonomic Nervous System Center, Sao Paulo State University, UNESP, Marilia, SP, Brazil., Raimundo RD; School of Medicine of ABS, Santo Andre, SP, Brazil., de Souza IS; School of Medicine of ABS, Santo Andre, SP, Brazil., Dos Santos Chagas A; Autonomic Nervous System Center, Sao Paulo State University, UNESP, Marilia, SP, Brazil., Folegatti DRMA; Autonomic Nervous System Center, Sao Paulo State University, UNESP, Marilia, SP, Brazil., Dos Santos GC; Autonomic Nervous System Center, Sao Paulo State University, UNESP, Marilia, SP, Brazil., Porto AA; Autonomic Nervous System Center, Sao Paulo State University, UNESP, Marilia, SP, Brazil., Benjamim CJR; Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, Brazil., Garner DM; Cardiorespiratory Research Group, Department of Biological and Medical Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Headington Campus, Gipsy Lane, Oxford OX3 0BP, United Kingdom., Valenti VE; Autonomic Nervous System Center, Sao Paulo State University, UNESP, Marilia, SP, Brazil. Electronic address: vitor.valenti@unesp.br.
Jazyk: angličtina
Zdroj: Journal of affective disorders [J Affect Disord] 2024 Jun 15; Vol. 355, pp. 200-209. Date of Electronic Publication: 2024 Mar 20.
DOI: 10.1016/j.jad.2024.03.071
Abstrakt: Introduction: The impacts of antidepressant pharmacotherapies on cardiovascular risk are unclear. We completed a systematic review with meta-analysis to assess the effect of paroxetine on heart rate variability (HRV) in patients with major depressive disorder (MDD).
Methods: The searches were accomplished via EMBASE, MEDLINE/PubMed (using the National Library of Medicine), Cochrane Library, CINAHL, Scopus, and Web of Science databases. We included non-blind, single, or double-blind randomized control trials in patients older than 18 diagnosed with MDD. Paroxetine needs to be enforced as a chronic therapeutic medication. We included individual studies that investigated resting HRV.
Results: We documented 402 studies, only following screening and eligibility phases; only six were included (five studies in the meta-analysis). No significant change was noticed for the SDNN index: subtotal = 8.23 [CI: -2.17, 18.63], p = 0.12, I2 = 54 % (very low quality of evidence). A significant change was distinguished for the LF index: subtotal = 0.74 [CI: 0.33, 1.15], p = 0.0004, I2 = 0 % (low quality of evidence). A significant alteration was perceived for the HF index: subtotal = 0.33 [CI: 0.06, 0.6], p = 0.02, I2 = 0 % (low quality of evidence).
Conclusion: Meta-analysis demonstrated that paroxetine could advance HRV in MDD patients. Nevertheless, our supposition is founded only on statistical analysis and the very low quality of evidence breakdown reinforces the necessity for further studies to confirm or reject this theory.
Competing Interests: Declaration of competing interest The authors declare no conflict of interest.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: